102 related articles for article (PubMed ID: 9854719)
21. [Prenatal maternal blood screening for the detection of fetal chromosomal abnormalities: clinical importance of the rate of false positives].
Alvarez-Nava F; Soto M; Padrón T; Morales A; Villalobos D; Rojas de Atencio A; Prieto M; Martínez MC
Invest Clin; 2003 Sep; 44(3):195-207. PubMed ID: 14552058
[TBL] [Abstract][Full Text] [Related]
22. Triploidy identified through second-trimester serum screening.
Huang T; Alberman E; Wald N; Summers AM
Prenat Diagn; 2005 Mar; 25(3):229-33. PubMed ID: 15791661
[TBL] [Abstract][Full Text] [Related]
23. A cost-effectiveness analysis of prenatal screening strategies for Down syndrome.
Odibo AO; Stamilio DM; Nelson DB; Sehdev HM; Macones GA
Obstet Gynecol; 2005 Sep; 106(3):562-8. PubMed ID: 16135588
[TBL] [Abstract][Full Text] [Related]
24. Urinary screening tests for fetal Down syndrome: II. Hyperglycosylated hCG.
Cole LA; Shahabi S; Oz UA; Rinne KM; Omrani A; Bahado-Singh RO; Mahoney MJ
Prenat Diagn; 1999 Apr; 19(4):351-9. PubMed ID: 10327141
[TBL] [Abstract][Full Text] [Related]
25. Comparison of serum markers in first-trimester down syndrome screening.
Canick JA; Lambert-Messerlian GM; Palomaki GE; Neveux LM; Malone FD; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Saade GR; Berkowitz RL; Dar P; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; D'Alton ME;
Obstet Gynecol; 2006 Nov; 108(5):1192-9. PubMed ID: 17077242
[TBL] [Abstract][Full Text] [Related]
26. Prospective evaluation of free beta-subunit of human chorionic gonadotropin and dimeric inhibin A for aneuploidy detection.
Wenstrom KD; Owen J; Chu Dc; Boots L
Am J Obstet Gynecol; 1999 Oct; 181(4):887-92. PubMed ID: 10521748
[TBL] [Abstract][Full Text] [Related]
27. Inclusion of serum marker measurements from a previous pregnancy improves Down syndrome screening performance.
Larsen SO; Christiansen M; Nørgaard-Pedersen B
Prenat Diagn; 1998 Jul; 18(7):706-12. PubMed ID: 9706652
[TBL] [Abstract][Full Text] [Related]
28. Estimates for the sensitivity and false-positive rates for second trimester serum screening for Down syndrome and trisomy 18 with adjustment for cross-identification and double-positive results.
Benn PA; Ying J; Beazoglou T; Egan JF
Prenat Diagn; 2001 Jan; 21(1):46-51. PubMed ID: 11180240
[TBL] [Abstract][Full Text] [Related]
29. Down's syndrome risk estimates demonstrate considerable heterogeneity despite homogeneity of input.
Reynolds T; Ellis A; Jones R
Ann Clin Biochem; 2004 Nov; 41(Pt 6):464-8. PubMed ID: 15588435
[TBL] [Abstract][Full Text] [Related]
30. Urinary free beta hCG, beta core fragment and total oestriol as markers of Down syndrome in the second trimester of pregnancy.
Hsu JJ; Spencer K; Aitken DA; Crossley J; Choi T; Ozaki M; Tazawa H
Prenat Diagn; 1999 Feb; 19(2):146-58. PubMed ID: 10215073
[TBL] [Abstract][Full Text] [Related]
31. Down syndrome maternal serum marker screening after 18 weeks' gestation.
Muller F; Dreux S; Oury JF; Luton D; Uzan S; Uzan M; Levardon M; Dommergues M
Prenat Diagn; 2002 Nov; 22(11):1001-4. PubMed ID: 12424764
[TBL] [Abstract][Full Text] [Related]
32. Alpha-fetoprotein, free beta-human chorionic gonadotropin, and dimeric inhibin A produce the best results in a three-analyte, multiple-marker screening test for fetal Down syndrome.
Wenstrom KD; Owen J; Chu DC; Boots L
Am J Obstet Gynecol; 1997 Nov; 177(5):987-91. PubMed ID: 9396880
[TBL] [Abstract][Full Text] [Related]
33. [Specificity of biochemical markers of pregnancy second trimester].
Salazar López R; Ibarra Gallardo AL; Iduma Meléndrez M; Leyva Bojórquez R
Ginecol Obstet Mex; 2007 Oct; 75(10):608-14. PubMed ID: 18800579
[TBL] [Abstract][Full Text] [Related]
34. Prediction of patient-specific risk for fetal loss using maternal characteristics and first- and second-trimester maternal serum Down syndrome markers.
Dugoff L; Cuckle HS; Hobbins JC; Malone FD; Belfort MA; Nyberg DA; Comstock CH; Saade GR; Eddleman KA; Dar P; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; D'Alton ME;
Am J Obstet Gynecol; 2008 Sep; 199(3):290.e1-6. PubMed ID: 18771987
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of Down's syndrome screening population data sets by simulation: analyser-specific parameters may be superior to meta-analysis-derived parameters.
Reynolds TM; Vranken G; Van Nueten J; Aldis J
Int J Clin Pract; 2008 May; 62(5):735-43. PubMed ID: 17590221
[TBL] [Abstract][Full Text] [Related]
36. Inhibin A is a maternal serum marker for Down's syndrome early in the first trimester.
Christiansen M; Nørgaard-Pedersen B
Clin Genet; 2005 Jul; 68(1):35-9. PubMed ID: 15952984
[TBL] [Abstract][Full Text] [Related]
37. Screening for trisomies 21 and 18 with maternal serum placental isoferritin p43 component.
Moroz C; Maymon R; Jauniaux E; Traub L; Cuckle H
Prenat Diagn; 2000 May; 20(5):395-9. PubMed ID: 10820407
[TBL] [Abstract][Full Text] [Related]
38. Contingent screening for Down syndrome--results from the FaSTER trial.
Cuckle HS; Malone FD; Wright D; Porter TF; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Ferreira JC; Dugoff L; Craigo SD; Timor IE; Carr SR; Wolfe HM; D'Alton ME
Prenat Diagn; 2008 Feb; 28(2):89-94. PubMed ID: 18236423
[TBL] [Abstract][Full Text] [Related]
39. Detection of maternal serum hCG glycoform variants in the second trimester of pregnancies affected by Down syndrome using a lectin immunoassay.
Talbot JA; Spencer K; Abushoufa RA
Prenat Diagn; 2003 Jan; 23(1):1-5. PubMed ID: 12533803
[TBL] [Abstract][Full Text] [Related]
40. Maternal serum-integrated screening for trisomy 18 using both first- and second-trimester markers.
Palomaki GE; Neveux LM; Knight GJ; Haddow JE
Prenat Diagn; 2003 Mar; 23(3):243-7. PubMed ID: 12627428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
